Table 4 Characteristics of BCS Cohort, Overall and by Fracture Status
Variable | Overall | No Fracture | Fracture |
|---|---|---|---|
Age years | 57.5 ± 4.9 | 57.1 ± 4.8 | 60.0 ± 5.2b |
BMI kg/m2 | 24.8 ± 3.7 | 24.9 ± 3.7 | 23.8 ± 3.3 |
Education ≥ High School | 156/200 (78) | 143/178 (80.3) | 13/22 (59.1)a |
Menarche years | 14.4 ± 2.0 | 14.5 ± 1.9 | 14.5 ± 2.1 |
Menopause years | 49.4 ± 4.0 | 49.4 ± 4.2 | 49.2 ± 2.2 |
Parity | |||
0 | 2/200 (1) | 2/178 (1.1) | 0/22 (0) |
1 | 137/200 (68.5) | 126/178 (70.8) | 11/22 (50)a |
≥ 2 | 61/200 (30.5) | 50/178 (28.1) | 11/22 (50)a |
Smoking, Ever | 6/200 (3) | 6/178 (3.4) | 0/22 (0) |
Current Alcohol Use | 11/200 (5.5) | 11/178 (6.2) | 0/22 (0) |
Fall in Past Year | 31/198 (15.7) | 28/176 (15.9) | 3/22 (13.6) |
Parental Fracture History | 20/188 (10.6) | 18/167 (10.8) | 2/21 (9.5) |
Personal Fracture History | 21/200 (10.5) | 19/178 (10.7) | 2/22 (9.1) |
Calcium Supplement | 96/196 (49) | 88/174 (50.6) | 8/22 (36.4) |
DXA Since Diagnosis | 54/200 (27) | 44/178 (24.7) | 10/22 (45.5)a |
Low BMD Since Diagnosis | 24/195 (12.3) | 22/173 (12.7) | 2/22 (9.1) |
CTx ng/mL | 0.458 ± 0.211 | 0.457 ± 0.209 | 0.463 ± 0.227 |
P1NP ng/mL | 61.1 ± 30.4 | 61.3 ± 30.1 | 58.9 ± 33.2 |
25OHD ng/mL | 20.3 ± 7.8 | 20.5 ± 7.6 | 19.0 ± 9.7 |
Postmenopausal at Diagnosis | 81/189 (42.9) | 67/167 (40.1) | 14/22 (63.6)a |
Duration of Breast Cancer | 6.3 ± 1.9 | 6.4 ± 2.0 | 6.1 ± 1.6 |
BrCa Stage at Diagnosis | |||
I | 77/183 (42.1) | 69/162 (42.6) | 8/21 (38.1) |
II | 79/183 (43.2) | 69/162 (42.6) | 10/21 (47.6) |
III | 27/183 (14.8) | 24/162 (14.8) | 3/21 (14.3) |
Hormone Receptor Status | |||
ER+/PR+ | 113/186 (60.1) | 100/164 (61) | 13/22 (59.1) |
ER+/PR- | 11/186 (5.9) | 10/164 (6.1) | 1/22 (4.6) |
ER-/PR+ | 33/186 (17.6) | 30/164 (18.3) | 3/22 (13.6) |
ER-/PR- | 29/186 (15.4) | 24/164 (14.6) | 5/22 (22.7) |
HER2 Receptor Positive | 38/183 (20.8) | 35/161 (21.7) | 3/22 (13.6) |
Surgery | 187/187 (100) | 165/165 (100) | 22/22 (100) |
Radiation Therapy | 53/182 (29.1) | 45/160 (28.1) | 8/22 (36.4) |
Chemotherapy | 153/185 (82.7) | 135/163 (82.8) | 18/22 (81.8) |
Endocrine Therapy | 158/189 (84) | 141/167 (84.4) | 17/22 (77.3) |
SERM | 70/188 (37.2) | 64/166 (38.6) | 6/22 (27.3) |
Aromatase Inhibitor | 90/189 (47.6) | 82/167 (49.1) | 8/22 (36.4) |
GnRH agonist | 2/189 (1.1) | 2/167 (1.2) | 0/22 (0) |
Ovariectomy | 16/189 (8.5) | 13/167(7.8) | 3/22 (13.6) |
Recurrence | 2/185 (1.1) | 2/162 (1.2) | 0/22 (0) |